A new chemotherapeutic target from Leishmania SPP. Understanding and inhibiting CYP61LD, a sterol C22 desaturase

利什曼原虫 SPP 的新化疗靶点。

• 批准号: DP110104455
• 负责人: Prof James De Voss
• 金额: $ 19.65万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP110104455
• 关键词: new; chemotherapeutic; target; Leishmania; SPP.

Leishamniasis is a debilitating and often fatal disease that is caused by a parasite, Leishmania sp., which is increasing its range to include Australia. This project aims to explore possible chemotherapeutics for the disease which inhibit a particular and unique enzyme the organism uses to synthesise the sterols it requires to live.

利什曼病是一种使人衰弱且往往致命的疾病，由一种寄生虫利什曼原虫引起，它的范围正在扩大，包括澳大利亚。该项目旨在探索可能的化疗方法，抑制生物体用于合成其生存所需的甾醇的一种特殊而独特的酶。